MINI LONG - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 17:28:10 27/06/2024 BST | ||
| 25.9 EUR | +0.35% |
|
| Current month | +10.06% | ||
| 1 month | +7.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 25.9 | +0.35% |
| 26/06/24 | 25.81 | +0.86% |
| 25/06/24 | 25.59 | -1.27% |
| 24/06/24 | 25.92 | +2.61% |
| 21/06/24 | 25.26 | -0.71% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 05:28 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KA4XNU |
| ISIN | DE000KA4XNU0 |
| Date issued | 04/10/2019 |
| Strike | 199 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.71 € |
|---|---|
| Lowest since issue | 1.17 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Certificates
- Certificat
